ED Implant denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ed implant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Your Penile Implant as Duplicate Therapy — and How to Appeal

A duplicate-therapy denial means Blue Cross Blue Shield has determined that a penile implant (inflatable or malleable penile prosthesis) provides the same clinical benefit as another treatment the patient is already receiving or that remains available. This denial typically arises when chart records show the patient has used or is currently using oral pharmacotherapy or injection therapy, and BCBS concludes the implant would simply replicate an existing treatment effect.

### Why This Denial Is Appealable

A penile implant is not therapeutically equivalent to oral or injectable medications for erectile dysfunction. It is a surgical intervention indicated specifically when non-surgical therapies have failed, are contraindicated, or are not tolerated. The clinical basis for "duplicate therapy" is weak when the record shows prior treatment failures. The American Urological Association (AUA) guideline supports surgical implantation as a treatment option for appropriate patients after conservative therapies have not provided adequate results — your prescriber can cite this guideline organization in the appeal without quoting specific statistics.

### Federal Appeal Framework

• Internal appeal: Submit a written appeal to BCBS within the deadline on your Explanation of Benefits. Request the specific coverage policy and the clinical criteria BCBS used to classify the implant as duplicative.
• External review (ACA §2719): If the internal appeal is denied, you have the right to independent external review. The window to request external review is approximately four months from the denial date for most plans; confirm your exact deadline on the denial letter.
• Expedited review: Available when delay would seriously jeopardize health. Decisions are typically required within 72 hours.
• ERISA §503: For employer-sponsored plans, you are entitled to a full-and-fair review with access to all documents used in the determination.

### What to Gather

1. Diagnosis confirmation — urologist's records confirming organic erectile dysfunction diagnosis and etiology (vascular, neurogenic, post-surgical, diabetes-related, etc.). 2. Prior treatment history with dates and outcomes — a dated log of all oral and injectable therapies tried, duration of each trial, and documented reason for discontinuation (inadequate response, adverse effects, medical contraindication, or patient-specific factors). 3. Distinction from current therapy — if patient is nominally on another therapy, urologist letter explaining why that therapy is not providing adequate clinical benefit and why continued parallel use is not appropriate. 4. Prescriber medical-necessity letter — explaining that the implant is not duplicative but is the clinically appropriate next step after documented failure of less invasive options, per AUA guidance. 5. BCBS coverage policy — obtain the exact policy version and copy each "duplicate therapy" criterion into your appeal response.

### Criteria-Mapping Structure

For each criterion BCBS cited to support the duplicate-therapy finding, write a one-sentence response citing the specific chart entry, date, and clinical outcome that refutes equivalence. The goal is to demonstrate that the implant occupies a distinct clinical role that prior or current therapies do not and cannot fill.